학술논문

A real-world survival of subsequent therapy in ALK positive non-small cell lung cancer (NSCLC) patients with crizotinib resistance.
Document Type
Journal
Source
JOURNAL OF CLINICAL ONCOLOGY; MAY 20 2018, 36 15, 1p. Supplement: S
Subject
Language
English
ISSN
15277755